Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes
CXCL13
DOI:
10.3389/fimmu.2023.1171978
Publication Date:
2023-06-24T10:12:47Z
AUTHORS (21)
ABSTRACT
Background Proinflammatory chemokines/cytokines support development and maturation of tertiary lymphoid structures (TLS) within the tumor microenvironment (TME). In current study, we sought to investigate prognostic value TLS-associated (TLS-kines) expression levels in melanoma patients by performing serum protein tissue transcriptomic analyses, then correlate these data with clinicopathological TME characteristics. Methods Levels TLS-kines patients’ sera were quantitated using a custom Luminex Multiplex Assay. The Cancer Genomic Atlas cohort (TCGA-SKCM) Moffitt Melanoma used for analyses. Associations between target analytes survival outcomes, variables, correlations statistically analyzed. Results Serum 95 evaluated; 48 (50%) female, median age 63, IQR 51-70 years. APRIL/TNFSF13 positively correlated both CXCL10 CXCL13. multivariate high associated improved event-free after adjusting stage (HR = 0.64, 95% CI 0.43-0.95; p 0.03). High transcripts was significantly OS TCGA-SKCM 0.69, 0.52-0.93; 0.01) 0.51, CI: 0.32-0.82; 0.006). Further incorporation CXCL13 transcript 3-gene index revealed that APRIL/CXCL10/CXCL13 TCGA SKCM 0.42, 0.19-0.94; 0.035). differentially expressed genes linked infiltration diverse array proinflammatory immune cell types. Conclusion are outcomes. Patients exhibiting coordinate their tumors displayed superior OS. investigation TLS-kine profiles related clinical outcomes larger studies is warranted.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....